Diagnostic performance and prognostic value of ^<18>F-FAMT PET in non-small cell lung cancer

对13 F-FAMT PET的诊断性能和价值<18>进行了检查，以验证在非小细胞肺癌（NSCLC）患者中的临床意义。~ 1F-FAMT PET的特异性<18>上级优于~ <18>1F-FDG PET。F-FAMT的摄取<18>与LAT 1表达以及细胞增殖和VEGF表达相关。与LAT 1阴性患者相比，LAT 1阳性患者的5年生存率显著缩短。LAT 1以及病理分期和CD 98表达是独立的预后因素，表明^18<F>-FAMT PET在NSCLC中的诊断和预后价值。

Diagnostic performance and value of ^<18>F-FAMT PET was examined to verify clinical implication in patients with non-small cell lung cancer (NSCLC). Specificity of ^<18>F-FAMT PET was superior to ^<18>F-FDG PET. The uptake of ^<18>F-FAMT was correlated with LAT1 expression as well as cellular proliferation and VEGF expression. Patients with positive LAT1 had significantly shorter 5-year survival as compared with negative LAT1. LAT1, as well as pathological stage and CD98 expression, was an independent prognostic factor, indicating diagnostic and prognostic value of ^18<F>-FAMT PET in NSCLC.